RESUMO
A osteoporose é caracterizada pela perda óssea e pelo comprometimento da resistência do osso. Essa patologia afeta, também, os ossos da face e consequentemente interfere na atuação dos profissionais da odontologia. Assim sendo, o presente trabalho revisou a literatura acerca da relação entre osteoporose e odontologia. O levantamento dos dados se deu por consulta a livros e nas bases de dados Biblioteca Virtual em Saúde (BVS), PubMed e Scientific Eletronic Library Online (SciELO) e como Descritores em Ciência da Saúde (Decs) foram adotados os termos: "Odontologia", "Osteoporose" e "Saúde bucal". A osteoporose diminui a massa e aumenta a porosidade óssea na maxila e na mandíbula, podendo provocar até quatro vezes mais perda dentária. Os bifosfonatos, principal classe medicamentosa utilizada para o tratamento de osteoporose, estão associados à ocorrência de osteonecrose dos maxilares e ao aumento de tempo de tratamento ortodôntico. Assim, pode-se concluir que é imprescindível o conhecimento do cirurgião-dentista acerca da osteoporose para uma segura abordagem e execução de tratamento.
Osteoporosis is characterized by bone loss and compromised bone strength. This pathology also affects the bones of the face and consequently interferes with the work of dentists. Therefore, the present study reviewed the literature about the relationship between osteoporosis and dentistry. Data collection was carried out by consulting books and the databases Biblioteca Virtual em Saúde (BVS), PubMed and Scientific Electronic Library Online (SciELO) and as Medical Subjects Headings (MeSH) the terms adopted were: "Dentistry", "Osteoporosis" and "Oral health". Osteoporosis reduces bone mass and increases bone porosity in the maxilla and jaw, which can cause up to four times more tooth loss. Bisphosphonates, the main class of medications used to treat osteoporosis, are associated with the occurrence of osteonecrosis of the jaw (ONJ) and increase the time of orthodontic treatment. Thus, it can be concluded that the dentist's knowledge of osteoporosis is necessary for a safe approach and execution of treatment.
Assuntos
Osteoporose , Saúde Bucal , Odontologia , DifosfonatosRESUMO
INTRODUCTION: Sarcopenia and Osteoporosis are two prevalent conditions in the older population and are defined by low strength, muscle quality/volume and low Bone Mineral Density, respectively. When there is a concomitant presence of both, there is a novel musculoskeletal condition called Osteosarcopenia. These conditions adversely affect quality of life and elevate the risk of fractures, disability, and mortality among older individuals. Dysbiosis of the gut microbiota is the impairment of the mutualistic relationship between microorganisms, metabolic products and the host's immune system. Gut microbiota dysbiosis could be intricately linked to sarcopenia and osteoporosis, shedding light on the complex microbiota-gut-bone-muscle axis. Furthermore, the intestinal microbiota experiences a notable decline in beneficial microorganisms as part of the aging process. The relationship between dysbiosis of the intestinal microbiota in older people and sarcopenia, osteoporosis or osteosarcopenia is still unclear. This review protocol aims to systematically review the literature and compile evidence on the influence of gut microbiota dysbiosis on musculoskeletal function in older people with sarcopenia, osteoporosis or osteosarcopenia. METHODS/ANALYSIS: This systematic review will analyze observational studies that have investigated the relationship between the effects of gut microbiota dysbiosis and sarcopenia, osteoporosis and osteosarcopenia in older people aged 65 and over. Studies will be retrieved from PubMed/MEDLINE, EMBASE, Scopus, Web of Science and the Cochrane Library. Outcome measures will include body composition for diagnosing osteoporosis and screening for sarcopenia/osteosarcopenia by any criteria. Data synthesis will involve quantitative analysis using summary measures. If sufficient studies, homogeneity and heterogeneity analysis will be performed to conduct Meta-analysis and pooled OR, RR and HR measures will be provided.
Assuntos
Disbiose , Microbioma Gastrointestinal , Osteoporose , Sarcopenia , Revisões Sistemáticas como Assunto , Humanos , Sarcopenia/microbiologia , Osteoporose/microbiologia , Disbiose/complicações , Disbiose/microbiologia , IdosoRESUMO
Patients with radiographic axial spondyloarthritis (r-axSpA) experience a higher prevalence of fragility fractures, though the pathophysiology of osteoporosis associated with this disease remains poorly understood. The objective of this study was to evaluate the histomorphometric data in r-axSpA patients. Male r-axSpA patients up to 55 years old were enrolled in this cross-sectional study. Clinical, lab, and imaging data, including spine X-Ray to evaluate vertebral fractures and new bone formation, as well as dual-energy X-ray absorptiometry (DXA) at spine, hip, and forearm and trabecular bone score (TBS), were performed in all patients. Transiliac histomorphometry was also underwent in all patients, and data were compared with 21 male cadavers' material. A total of 21 patients were included, with a mean age of 45.8 years, long disease duration (median 17.5 years), mostly white (66.7%) and positive for HLA-B27 (90.5%). The prevalence of DXA abnormalities and low TBS (≤ 1.338) was 42.8% and 57.1%, respectively. There was higher osteoid trabecular thickness (p = 0.027) and cortical bone changes, including reduced thickness (p = 0.031) and increased porosity (p = 0.015) in r-axSpA patients. In addition, a pattern of cortical trabecularization was observed in 52.3%. Dynamic evaluation revealed a longer mineralization lag time (p = 0.0074) and lower mineralized surface (p = 0.0029) and bone formation rate (p = 0.0074) in patients compared to reference values. Our results showed a pattern of low trabecular remodeling, bone mineralization impairment, as well as cortical thickness and porosity abnormalities in men with r-axSpA. These findings may impact future treatment of bone fragility in this disease.
Assuntos
Absorciometria de Fóton , Espondiloartrite Axial , Densidade Óssea , Remodelação Óssea , Humanos , Masculino , Pessoa de Meia-Idade , Remodelação Óssea/fisiologia , Estudos Transversais , Adulto , Densidade Óssea/fisiologia , Espondiloartrite Axial/epidemiologia , Osso Cortical/diagnóstico por imagem , Osso Cortical/patologia , Osteoporose/patologia , Calcificação Fisiológica/fisiologiaRESUMO
Surface treatments play an important role in enhancing the osseointegration of Titanium (Ti) and its alloys. This study introduces a method employing biomimetic hydroxyapatite (Hap) deposition guided by molecularly organized phospholipids, affixed to the metal implant surface. Using the Langmuir-Blodgett technique, phospholipids were deposited onto Ti-screws by using CaCl2 or CaCl2/SrCl2 aqueous solution in the subphase of a Langmuir trough in the target proportion (i.e. 10 and 90 mol% of Sr2+ in relation of Ca2+) followed by immersion in phosphate buffer and in supersaturated simulated body fluid. Coating composition and morphology were evaluated using infrared spectroscopy and scanning electron microscopy, respectively, while contact angle measurements assessed coating wettability and surface energy. Randomized screws were then implanted into the tibias of healthy and osteoporotic female rats (G1: Control-Machined, G2: Hap, G3: HapSr10, G4: HapSr90). Osseointegration, assessed 60 days post-implantation, included reverse torque, fluorochrome area, bone tissue-screw contact area, and linear extent of bone-screw contact. Results, grouped by surface treatment (Machined, Hap, HapSr10, HapSr90), revealed that the deposition of Hap, HapSr10, and HapSr90 resulted in thin and rough coatings composed of hydroxyapatite (Hap) on the screw surface with nanoscale pores. The coatings resulted in increased wettability and surface energy of Ti surfaces. The minerals are chemically similar to natural bone apatite as revealed by FTIR analysis. In vivo analyses indicated higher torque values for strontium-containing surfaces in the osteoporotic group (p = 0.02) and, in the control group superior torque for screw removal on the Hap surface (p = 0.023). Hydroxyapatite-treated surfaces enhance morphology, composition, and reactivity, promoting screw osseointegration in healthy and osteoporotic female rats. The incorporation of strontium into the mineral phase has been proposed to not only stimulate osteoblast activity but also reduce osteoclastic resorption, which may explain the improved outcomes observed here in experimental osteoporotic conditions.
Assuntos
Materiais Revestidos Biocompatíveis , Osseointegração , Osteoporose , Fosfolipídeos , Estrôncio , Animais , Osseointegração/efeitos dos fármacos , Materiais Revestidos Biocompatíveis/química , Materiais Revestidos Biocompatíveis/farmacologia , Estrôncio/farmacologia , Estrôncio/química , Feminino , Fosfolipídeos/química , Ratos , Osteoporose/tratamento farmacológico , Titânio/química , Titânio/farmacologia , Ratos Sprague-Dawley , Parafusos Ósseos , Durapatita/química , Durapatita/farmacologia , Propriedades de SuperfícieRESUMO
Epidemiologic and economic data regarding osteoporotic fractures in Mexico is scarce and mostly outdated. Through a model, we estimated the incidence and costs of osteoporotic fractures in adults ≥ 50 years old in Mexico during the year 2023. Results showed that these events are both frequent and costly, leading to a considerable economic impact. PURPOSE: Osteoporosis and its fractures impose a high clinical and economic burden. The objective of this analysis was to estimate the frequency and costs owing to incident fragility fractures (FFs) during the year 2023 in Mexico. METHODS: This is an incidence-based cost-of-illness study. The target population is adults ≥ 50 years old sustaining a fracture related to osteoporosis (caused by a fall on the same level). The model estimates the costs and productivity losses associated with their treatment within 1 year post-fracture. National epidemiologic databases supplemented with information, derived from literature when appropriate, were used to estimate the frequency of new FFs during 2023 in the study population. Resource use included surgical and non-surgical inpatient or ambulatory care the patients received immediately after fracture plus the outpatient physiotherapy post-discharge and the eventual follow-up with a specialist who may prescribe pharmacotherapy. Sick days taken in employed patients were estimated from the literature. Local unitary costs of services and drugs for both public and private settings as well as average income in those occupied were applied. All costs are reported in Mexican pesos (MXN) from 2023. RESULTS: The model estimated a total of 229,239 FFs, among which 63% were classified as a major osteoporotic fracture, including 53,842 and 41,459 fractures located at the hip and vertebral, respectively. The total costs were estimated at 15,593 million MXN; most of them (75.2%) were attributable to acute-phase care. CONCLUSIONS: Fragility fractures represent a serious health problem for Mexico. Better preventive/therapeutic strategies may help to mitigate their significant financial toll.
Assuntos
Efeitos Psicossociais da Doença , Custos de Cuidados de Saúde , Fraturas por Osteoporose , Humanos , México/epidemiologia , Fraturas por Osteoporose/economia , Fraturas por Osteoporose/epidemiologia , Fraturas por Osteoporose/terapia , Pessoa de Meia-Idade , Incidência , Idoso , Feminino , Masculino , Custos de Cuidados de Saúde/estatística & dados numéricos , Idoso de 80 Anos ou mais , Osteoporose/economia , Osteoporose/epidemiologia , Osteoporose/complicaçõesRESUMO
Zoledronic acid is a widely used bisphosphonate for treating osteoporosis and hypercalcemia related to malignancy. It is also used to prevent bone loss induced by cancer treatment and bone metastases in various cancer types. Zoledronic acid is safe for most patients and is generally not associated with severe side effects. However, there have been reports of acute kidney impairment occurring after administration of intravenous zoledronic acid, mostly in patients with cancer (who received a high cumulative dose of this medication) or preexisting kidney impairment, and in patients with a history of nephrotoxic treatment. We report herein the cases of two patients without history of cancer, who developed dialysis-requiring acute kidney impairment after a single administration of intravenous zoledronic acid. None of the patients had previously used nephrotoxic medications, and one of them had a normal kidney function before zoledronic acid treatment. To the best of our knowledge, this report describes the first case of acute kidney impairment in a patient without risk factors. The findings of this report show that acute kidney impairment following intravenous zoledronic acid treatment can also occur in low-risk patients, highlighting the need for monitoring kidney function in all patients receiving this treatment.
Assuntos
Injúria Renal Aguda , Conservadores da Densidade Óssea , Difosfonatos , Imidazóis , Osteoporose , Diálise Renal , Ácido Zoledrônico , Humanos , Ácido Zoledrônico/administração & dosagem , Ácido Zoledrônico/uso terapêutico , Conservadores da Densidade Óssea/administração & dosagem , Conservadores da Densidade Óssea/efeitos adversos , Conservadores da Densidade Óssea/uso terapêutico , Injúria Renal Aguda/induzido quimicamente , Imidazóis/administração & dosagem , Imidazóis/efeitos adversos , Difosfonatos/administração & dosagem , Difosfonatos/efeitos adversos , Feminino , Osteoporose/tratamento farmacológico , Infusões Intravenosas , Idoso , Pessoa de Meia-Idade , MasculinoRESUMO
OBJECTIVES: Aging involves significant changes in body composition, marked by declines in muscle mass and bone mineral density alongside an increase in fat mass. Sarcopenia is characterized by low strength and muscle mass, and osteosarcopenia is the coexistence of sarcopenia and osteopenia/osteoporosis. Physiologically, there is a crosstalk between muscle and bone tissues mediated by several pathways. Both, sarcopenia and osteosarcopenia, have been related with adverse outcomes such as functional disability. However, there is a lack of longitudinal studies. Therefore, this study aimed to assess whether sarcopenia and osteosarcopenia phenotypes increased the risk of functional disability in a longitudinal cohort of community-dwelling adults. DESIGN: This study constitutes a secondary longitudinal analysis of data derived from the prospective cohort FraDySMex (Frailty, Dynapenia, and Sarcopenia in Mexican adults). SETTING AND PARTICIPANTS: FraDySMex is conducted in community-dwelling adults aged 50 years or older living in Mexico City. Data from 2014 to 2015 was considered as baseline evaluation, and the 2019 wave was the follow-up evaluation. Individuals with complete baseline and follow-up evaluations were included in the analysis. MEASUREMENTS: Sarcopenia diagnosis adhered to the FNIH criteria, while osteopenia/osteoporosis classification followed WHO guidelines. Osteosarcopenia was defined as the concurrent presence of sarcopenia and osteopenia/osteoporosis. Functional disability was identified by the Lawton Instrumental Activities of Daily Living (IADL) Scale. Adjusted mixed-effects logistic regression models were estimated to evaluate the effect of body composition phenotype on the risk of functional disability. RESULTS: The final sample included 320 adults with complete longitudinal data. The majority of were women (83.4%) and had 7-12 years of education (48.4%). At the baseline evaluation, 50.9% aged 50-70. The osteosarcopenia phenotype was associated with a higher risk of functional disability (OR: 2.17, p = 0.042) compared with the no osteopenia/sarcopenia group. Conversely, sarcopenia (OR: 1.50, p = 0.448) and osteopenia/osteoporosis (OR: 1.50, p = 0.185) phenotypes were not associated with functional disability. CONCLUSIONS: Our study underscores that osteosarcopenia significantly increased the risk of functional disability, particularly in terms of Instrumental Activities of Daily Living (IADL). These results emphasize the importance of screening for sarcopenia, osteopenia/osteoporosis, and osteosarcopenia across various clinical settings. Early detection and intervention hold promise for averting functional disability and mitigating associated adverse outcomes in adults.
Assuntos
Doenças Ósseas Metabólicas , Vida Independente , Sarcopenia , Humanos , Sarcopenia/epidemiologia , Feminino , Masculino , Estudos Longitudinais , Pessoa de Meia-Idade , Idoso , México/epidemiologia , Vida Independente/estatística & dados numéricos , Doenças Ósseas Metabólicas/epidemiologia , Estudos Prospectivos , Osteoporose/epidemiologia , Osteoporose/complicações , Fatores de Risco , Atividades Cotidianas , Fragilidade/epidemiologia , Fragilidade/complicações , Composição Corporal , Pessoas com Deficiência/estatística & dados numéricos , Estudos de Coortes , Densidade ÓsseaRESUMO
Osteoporosis (OP) is a chronic disease that affects older adults' quality of life, with fragility fractures (FF) being its most significant consequence due to their impact on healthcare systems in terms of morbidity, and economic and caregiving burden. FF are defined as fractures resulting from low-energy trauma, defined as falls from a standing height or less, and are usually considered osteoporotic (1). World demographic projections warn of a significant increase in adults aged 65 and older by 2050. These demographic changes mean that OP and FF will soon become an even greater challenge for healthcare systems, where prevention programs should be a priority. In Mexico, FF is also a public health challenge, with an initial reported incidence of nearly 2,000 cases per 100,000 population, and a projected seven-fold increase by 2050. Given this scenario, there is an urgent need for policy- and decision-makers to change their approach and formulate health policies that guarantee that people aged 65 and older are screened for fractures and have access to appropriate care. These policies should be part of a strategy to minimize FF and ensure active and healthy aging according to the WHO's Decade of Healthy Ageing. In this context, a group of Mexican experts representing different health organizations interested in the burden of OP and FF met to discuss possible strategies to reduce their burden for the next decade and summarize them in this Call to Action to promote public policies that prioritize an evidence-based approach to the prevention and treatment of OP and FF.
Assuntos
Osteoporose , Humanos , México/epidemiologia , Osteoporose/epidemiologia , Idoso , Fraturas por Osteoporose/epidemiologia , Fraturas por Osteoporose/prevenção & controle , Feminino , Masculino , Política de Saúde , Incidência , Qualidade de Vida , Idoso de 80 Anos ou maisRESUMO
What are the fractures associated with osteoporosis in Colombian persons over 50 years of age? Through the analysis of the Ministry of Health databases, Colombians over 50 years of age with osteoporosis fracture the forearm the most, followed by the thoracolumbar vertebrae and then the hip. We describe the differences between men and women. PURPOSE: The aim of this study was to determine the frequency of all bone fractures among adults aged 50 and above, both with and without osteoporosis, using data from SISPRO (Integrated Information System for Social Protection), the administrative database of the Colombian Ministry of Health. METHODS: Information was collected for the years 2017 to 2021 for all bone fractures (except cranial or face fractures), and how many of them occurred in patients who had the diagnosis of osteoporosis. Prevalence ratios (PR) were estimated separately for males and females by dividing the prevalence in those with by the prevalence of those without osteoporosis. RESULTS: For the period from 2017 to 2021, 303,037 adults over 50 years of age (females 279,057, 92.1%) were diagnosed with osteoporosis in Colombia, for a prevalence of 39.4 per thousand women and 4.14 in men; 40,823 of these women (14.6%) presented a fracture in the period, as well as 4020 of men (16.7%). Osteoporosis was present in 7.5% of the 596.618 (females 369.795; 62.0%) who suffered any fracture (1.8% of males and 11.0% of females). Overall PR was 3.4 (males 4.3; females 3.3). In men with osteoporosis, the most frequent fractures were hip (902), followed by lumbar vertebrae (842), ribs (648), and forearm (538), while in women, forearm (11,001), followed by hip (6885), lumbar vertebra (4813), and thoracic vertebra (2701) were the most common. PR in men was 21.9 for dorsal vertebrae fracture, 21.3 for lumbar vertebrae, 11.8 for ribs, and 7.7 for hip fracture. In women, PR was 15.7 for thoracic vertebrae, 13.3 for lumbar vertebrae, 3.3 for hip fracture, and 2.2 for forearm fracture. CONCLUSION: Osteoporosis is a highly prevalent disease in Colombia where women are more affected. Although fractures were more common in women, men with osteoporosis have a higher PR of associated fractures.
Assuntos
Osteoporose , Fraturas por Osteoporose , Humanos , Colômbia/epidemiologia , Masculino , Feminino , Pessoa de Meia-Idade , Prevalência , Idoso , Osteoporose/epidemiologia , Osteoporose/complicações , Fraturas por Osteoporose/epidemiologia , Idoso de 80 Anos ou mais , Distribuição por SexoRESUMO
The incidence of osteoporosis and related fractures increases significantly with age, impacting public health and associated costs. Postmenopausal osteoporosis results from increased bone resorption due to decreased estrogen levels. The endocannabinoid system, especially cannabidiol (CBD), has shown therapeutic potential in modulating bone formation. This study investigated the effects of administration of CBD in rats after the onset of with ovariectomy-induced osteopenia (OVX). Forty-eight female SpragueâDawley rats were divided into four groups (n = 12): OVX + CBD, SHAM + CBD, OVX + vehicle, and SHAM + vehicle. CBD was administered intraperitoneally for 3 weeks. After euthanasia, the bone quality, mechanical properties, and bone microarchitecture of the femurs and lumbar vertebrae were assessed by microcomputed tomography (micro-CT), bone densitometry, mechanical tests, and histological and immunohistochemical analyses. CBD treatment improved the bone mineral density (BMD) of the lumbar vertebrae and increased the BV/TV% and Tb.N in the femoral neck. There were also improvements in the mechanical properties, such as the maximum force and stiffness of the femurs and vertebrae. CBD significantly increased the bone matrix in osteopenic femurs and vertebrae, Although did not significantly influence the expression of RANKL and OPG, in ovariectomized animals, there was an increase in osteoblasts and a decrease in osteoclasts. Determining the optimal timing for CBD use in relation to postovariectomy bone loss remains a crucial issue. Understanding when and how CBD can be most effective in preventing or treating bone loss is essential to emphasize the importance of early diagnosis and treatment of osteoporosis. However, further studies are needed to explore in more detail the efficacy and safety of CBD in the treatment of postmenopausal osteoporosis.
Assuntos
Densidade Óssea , Canabidiol , Ovariectomia , Ratos Sprague-Dawley , Animais , Feminino , Canabidiol/farmacologia , Densidade Óssea/efeitos dos fármacos , Ratos , Microtomografia por Raio-X , Doenças Ósseas Metabólicas/tratamento farmacológico , Doenças Ósseas Metabólicas/metabolismo , Vértebras Lombares/efeitos dos fármacos , Osteoporose/tratamento farmacológico , Osteoporose/metabolismo , Fêmur/efeitos dos fármacos , Fêmur/metabolismo , Fêmur/diagnóstico por imagem , Osso e Ossos/efeitos dos fármacos , Osso e Ossos/metabolismoRESUMO
OBJECTIVE: Osteoporosis, defined as a systemic skeletal disease, is characterized by increased bone fragility and fracture risk. Studies have shown that dysregulation of the functions of miRNAs or the mechanisms they mediate may be an important pathological factor in bone degeneration. Therefore, the aim of the study was to determine the role of miRNAs, which are thought to play a role in bone metabolism, in osteoporosis. METHODS: The study included 48 patients who were diagnosed with osteoporosis according to the results of a bone mineral density assessment by quantitative computed tomography and 36 healthy individuals. MiRNAs from plasma samples obtained from blood samples taken into ethylenediaminetetraacetic acid (EDTA) tubes were isolated with the miRNA isolation kit and converted to cDNA. Expression analysis of miR-21-5p, miR-34a-5p, miR-210, miR-122-5p, miR-125b-5p, miR-133a, miR-143-3p, miR-146a, miR-155-5p, and miR-223 was performed on the real-time PCR (RT-PCR) device. RESULTS: When miRNA expression levels in the patient group were compared with the control group, all miRNAs were found to be downregulated in the patients. When fold changes in expression levels in the patient group were examined, significant differences were found in miR-21-5p, miR-133a, mir143-3p, miR-210, and miR-223. In the receiver operating curve analysis, area under the curve=0.882 for the combination of miR-34, miR-125, miR-133, and miR-210. CONCLUSION: In this study, it was determined that the combined effects of miRNAs, as well as their single effects, were effective in the development of osteoporosis. Therefore, a miRNA panel to be created can make a significant contribution to the development of novel diagnostic and treatment approaches for this disease.
Assuntos
MicroRNA Circulante , MicroRNAs , Osteoporose , Reação em Cadeia da Polimerase em Tempo Real , Humanos , Osteoporose/genética , Osteoporose/sangue , Feminino , Pessoa de Meia-Idade , Masculino , Estudos de Casos e Controles , MicroRNA Circulante/sangue , MicroRNA Circulante/genética , MicroRNAs/sangue , Idoso , Densidade Óssea/genética , Biomarcadores/sangue , Regulação para Baixo , AdultoRESUMO
This study investigated the effects of ovariectomy and caffeine intake on bone health in rats on calcium-deficient diet. Forty adults female Wistar rats were divided into 4 groups in a 2x2 factorial design: Ovary (OVX/SHAM) and Caffeine (placebo/caffeine). The animals were housed in individual cages for 8 weeks, receiving 18-20g of AIN-93M diet per day, containing 50% of the daily recommended intake of calcium. The rats underwent ovariectomy (OVX) or laparotomy (SHAM) surgery. Caffeine groups received 6mg of caffeine/kg/day. After euthanasia, the tibia and femur were dissected to determine the calcium content and bone fracture strength, respectively. Blood sample was collected to determine serum Ostase. 24-hour urine was analyzed for excreted calcium and NTx. Reduced bone fracture strength and calcium content were observed in OVX and Caffeine groups. When observed separately, OVX group showed increased urinary NTx and lower bone weight, blood ostase, and urinary calcium. Caffeine groups showed elevated urinary calcium. There was a positive correlation between bone fracture strength and calcium content. NTx correlated negatively with bone calcium, fracture strength and thickness. In conclusion, both OVX and caffeine intake debilitate bone health in rats on calcium-deficient diet.
Assuntos
Densidade Óssea , Cafeína , Cálcio , Ovariectomia , Ratos Wistar , Animais , Feminino , Cafeína/administração & dosagem , Cálcio/sangue , Cálcio/urina , Cálcio/análise , Densidade Óssea/efeitos dos fármacos , Ratos , Cálcio da Dieta/administração & dosagem , Cálcio da Dieta/análise , Osteoporose , Fraturas ÓsseasRESUMO
Bisphosphonates are widely used for the treatment of postmenopausal osteoporosis; however, they cause several long-term side effects, necessitating the investigation of local ways to improve osseointegration in compromised bone tissue. The purpose of this study was to evaluate peri-implant bone repair using implants functionalized with zoledronic acid alone (OVX ZOL group, n = 11), zoledronic acid + teriparatide (OVX ZOL + TERI group, n = 11), and zoledronic acid + ruterpy (OVX ZOL + TERPY group, n = 11) compared to the control group (OVX CONV, n = 11). Analyses included computer-assisted microtomography, qualitative histologic analysis, and real-time PCR analysis. Histologically, all functionalized surfaces improved peri-implant repair, with the OVX ZOL + TERI group standing out. Similar results were found in computerized microtomography analysis. In real-time PCR analysis, however, the OVX ZOL and OVX ZOL + TERPY groups showed better results for bone formation, with the OVX ZOL + TERPY group standing out, while there were no statistical differences between the OVX CONV and OVX ZOL + TERI groups for the genes studied at 28 postoperative days. Nevertheless, all functionalized groups showed a reduced rate of bone resorption. In short, all surface functionalization groups outperformed the control group, with overall better results for the OVX ZOL + TERI group.
Assuntos
Osteoporose , Ácido Zoledrônico , Animais , Ratos , Feminino , Ácido Zoledrônico/administração & dosagem , Ácido Zoledrônico/farmacologia , Osteoporose/tratamento farmacológico , Microtomografia por Raio-X , Osseointegração/efeitos dos fármacos , Conservadores da Densidade Óssea/administração & dosagem , Conservadores da Densidade Óssea/farmacologia , Conservadores da Densidade Óssea/uso terapêutico , Sistemas de Liberação de Medicamentos/métodos , Difosfonatos/administração & dosagem , Osteogênese/efeitos dos fármacosRESUMO
Due to bioactive properties, introducing spongin-like collagen (SPG) into the biosilica (BS) extracted from marine sponges would present an enhanced biological material for improving osteoporotic fracture healing by increasing bone formation rate. Our aim was to characterize the morphology of the BS/SPG scaffolds by scanning electron microscopy (SEM), the chemical bonds of the material by Fourier transform infrared spectroscopy (FTIR), and evaluating the orthotopic in vivo response of BS/SPG scaffolds in tibial defects of osteoporotic fractures in rats (histology, histomorphometry, and immunohistochemistry) in two experimental periods (15 and 30 days). SEM showed that scaffolds were porous, showing the spicules of BS and fibrous aspect of SPG. FTIR showed characteristic peaks of BS and SPG. For the in vivo studies, after 30 days, BS and BS/SPG showed a higher amount of newly formed bone compared to the first experimental period, observed both in the periphery and in the central region of the bone defect. For histomorphometry, BS/SPG presented higher %BV/TV compared to the other experimental groups. After 15 days, BS presented higher volumes of collagen type I. After 30 days, all groups demonstrated higher volumes of collagen type III compared to volumes at 15 days. After 30 days, BS/SPG presented higher immunostaining of osteoprotegerin compared to the other experimental groups at the same experimental period. The results showed that BS and BS/SPG scaffolds were able to improve bone healing. Future research should focus on the effects of BS/SPG on longer periods in vivo studies.
Assuntos
Colágeno , Poríferos , Alicerces Teciduais , Animais , Ratos , Alicerces Teciduais/química , Poríferos/química , Colágeno/metabolismo , Feminino , Dióxido de Silício/química , Osteoporose/patologia , Ratos Wistar , Fraturas por Osteoporose , Microscopia Eletrônica de Varredura , Osteogênese/efeitos dos fármacos , Espectroscopia de Infravermelho com Transformada de Fourier , TíbiaRESUMO
PURPOSE OF THE REVIEW: Osteosarcopenia is a geriatric syndrome associated with disability and mortality. This review summarizes the key microRNAs that regulate the hallmarks of sarcopenia and osteoporosis. Our objective was to identify components similarly regulated in the pathology and have therapeutic potential by influencing crucial cellular processes in both bone and skeletal muscle. RECENT FINDINGS: The simultaneous decline in bone and muscle in osteosarcopenia involves a complex crosstalk between these tissues. Recent studies have uncovered several key mechanisms underlying this condition, including the disruption of cellular signaling pathways that regulate bone remodeling and muscle function and regeneration. Accordingly, emerging evidence reveals that dysregulation of microRNAs plays a significant role in the development of each of these hallmarks of osteosarcopenia. Although the recent recognition of osteosarcopenia as a single diagnosis of bone and muscle deterioration has provided new insights into the mechanisms of these underlying age-related diseases, several knowledge gaps have emerged, and a deeper understanding of the role of common microRNAs is still required. In this study, we summarize current evidence on the roles of microRNAs in the pathogenesis of osteosarcopenia and identify potential microRNA targets for treating this condition. Among these, microRNAs-29b and -128 are upregulated in the disease and exert adverse effects by inhibiting IGF-1 and SIRT1, making them potential targets for developing inhibitors of their activity. MicroRNA-21 is closely associated with the occurrence of muscle and bone loss. Conversely, microRNA-199b is downregulated in the disease, and its reduced activity may be related to increased myostatin and GSK3ß activity, presenting it as a target for developing analogues that restore its function. Finally, microRNA-672 stands out for its ability to protect skeletal muscle and bone when expressed in the disease, highlighting its potential as a possible therapy for osteosarcopenia.
Assuntos
MicroRNAs , Músculo Esquelético , Osteoporose , Sarcopenia , Humanos , MicroRNAs/metabolismo , Sarcopenia/metabolismo , Sarcopenia/genética , Osteoporose/genética , Osteoporose/metabolismo , Músculo Esquelético/metabolismo , Remodelação Óssea , Fator de Crescimento Insulin-Like I/metabolismo , Transdução de Sinais , Miostatina/metabolismoRESUMO
INTRODUÇÃO: A osteoporose é uma enfermidade que aumenta a fragilidade óssea e suscetibilidade à fratura. No mundo, afeta aproximadamente 200 milhões de pessoas. Sua prevalência no Brasil varia de 6% a 33%. O tratamento indicado inclui estratégias medicamentosas e não medicamentosas. Entre as primeiras, encontram-se o carbonato de cálcio e a vitamina D como parte de todos os esquemas terapêuticos; os agentes anti reabsortivos (bisfosfonatos - alendronato, risedronato, pamidronato e ácido zoledrônico); o modulador seletivo dos receptores de estrogênio (raloxifeno); os estrógenos conjugados; calcitonina e o agente anabólico (teriparatida). Estas são opções disponíveis no Protocolo Clínico de Diretrizes Terapêuticas (PCDT) de Osteoporose do Sistema Único de Saúde (SUS). Em caso de falha terapêutica, que pode acompanhar 25% dos pacientes, as diretrizes clínicas nacionais e internacionais de sociedades médicas recomendam o uso de denosumabe ou teriparatida. Em portaria SCTIE/MS Nº 166, de 5 de dezembro de 2022, decidiu-se incorporar o romosozumabe para mulheres com osteoporose na pós menopausa, a partir de 70 anos, que apresentam risco muito alto de fratura por fragilidade em que houve falha (apresentaram duas ou mais fraturas) do padrão de tratamento medicamentoso, conforme protocolo est
Assuntos
Humanos , Osteoporose/tratamento farmacológico , Imunoglobulina G/farmacologia , Teriparatida/farmacologia , Sistema Único de Saúde , Brasil , Eficácia , Análise Custo-Benefício/economia , Pós-Menopausa/fisiologiaRESUMO
INTRODUÇÃO: A osteoporose é uma enfermidade que aumenta a fragilidade óssea e suscetibilidade à fratura. No mundo, afeta aproximadamente 200 milhões de pessoas. Sua prevalência no Brasil varia de 6% a 33%. O tratamento indicado inclui estratégias não medicamentosas e medicamentosas, entre as quais encontram-se o carbonato de cálcio e a vitamina D como parte de todos os esquemas terapêuticos; os agentes anti reabsortivos (bifosfonatos - alendronato, risedronato, pamidronato e ácido zoledrônico); o modulador seletivo dos receptores de estrogênio (raloxifeno); os estrógenos conjugados; calcitonina e o agente anabólico (teriparatida). Estas são opções disponíveis no Protocolo Clínico de Diretrizes Terapêuticas (PCDT) de Osteoporose do Sistema Único de Saúde (SUS). Em caso de falha terapêutica, que pode acompanhar 25% dos pacientes, as diretrizes clínicas nacionais e internacionais de sociedades médicas recomendam o uso de denosumabe, teriparatida ou romosozumabe, dependendo da população. O objetivo do presente relatório é analisar as evidências econômicas do uso da teriparatida para o tratamento da falha terapêutica em: (a) homens; (b) pacientes com osteoporose severa por uso de glicocorticoides (GC); (c) pacientes com acidente vascular cerebral (AVC); e d) pacientes com infarto agudo do miocárdio (IAM) no ano anterior. PERGUNTA: A teriparatida é custo-efetiva no tratamento de: (a) homens com osteoporose, (b) pacientes com osteoporose severa por uso de GC, (c) pacientes com AVC ou IAM no ano anterior, como alternativa aos bifosfonatos? AVALIAÇÃO ECONÔMICA: A avaliação de custo-efetividade não demonstrou a superioridade da teriparatida quando comparada ao alendronato e ao risedronato no tratamento de homens ou pacientes utilizando ou com AVC ou IAM. Para pacientes com uso de glicocorticoides, a razão de custo-efetividade incremental se situou em torno do limiar de R$ 40.000,00/QALY. ANÁLISE DE IMPACTO ORÇAMENTÁRIO: O impacto orçamentário, dependendo do market share, foi de 117 milhões para a população masculina, 17 milhões para pacientes usando glicocorticoides, 9,3 milhões com AVC e 10,3 milhões com IAM. O uso integral da teriparatida elevaria esse gasto para 187 milhões, 71 milhões, 37 milhões e 41 milhões, respectivamente. Deve-se observar que nesses valores pode haver dupla contagem, uma vez que as estimativas feitas para os homens não excluíram as comorbidades. EXPERIÊNCIAS INTERNACIONAIS/RECOMENDAÇÕES DE OUTRAS AGÊNCIAS DE ATS: Quanto ao uso da teriparatida em homens, o National Health System (NHS) a recomenda como alternativa de tratamento para a osteoporose secundária e prevenção de fraturas por fragilidade osteoporótica em homens intolerantes ao alendronato e risedronato ou com "resposta insatisfatória. É financiada pelo NHS England Specialized Commissioning. Na Nova Zelândia, a Pharmaceutical Management Agency (PHARMAC) sugere o financiamento da teriparatida como tratamento de última linha para a osteoporose, restringindo-a aos pacientes com evidência de fraturas contínuas e/ou T-escore <-3, após tentarem todos os tratamentos financiados para a osteoporose. Este uso está condicionado a uma redução significativa dos preços. A Austrália, por meio do The Pharmaceutical Benefits Scheme (PBS), incorporou a teriparatida para o tratamento de osteoporose grave em pacientes com risco alto de fratura com critérios muito bem estabelecidos. Deve ser a única terapia subsidiada pela PBS para esta condição, não excedendo um máximo de 18 meses. O informe de posicionamento terapêutico da teriparatida junto a Agência Espanhola de Medicamentos e Produtos Sanitários (AEMPS) indica seu uso para o tratamento de osteoporose em homens com aumento do risco de fratura. A Canadian Agency for Drugs and Technologies in Health (CADTH) não recomenda seu uso. A Pharmaceuticals and Medical Devices Agency (PMDA) do Japão não se posiciona quanto ao uso deste medicamento em homens com alto risco de fratura. O informe de posicionamento terapêutico para a teriparatida junto à AEMPS e à PMDA indicam seu uso para o tratamento de osteoporose associada à terapia sistêmica com GC, em homens e mulheres com incremento de risco de fratura. Não se encontrou posicionamento relacionado o seu uso em pacientes em uso de GC no sítio do NICE. O CADTH recomendou, em julho de 2009, a não incorporação do Forteo® para pessoas em uso de GC. Não se encontrou informe de posicionamento terapêutico para a teriparatida no tratamento de indivíduos com AVC ou IAM prévios, na PMDA, NICE, NHS, AEMPS ou PMDA. CONSIDERAÇÕES FINAIS: Na maioria dos cenários analisados, o uso dos bifosfonatos produz economia de recursos em relação à teriparatida no tratamento de homens ou com AVC ou IAM no ano anterior. A teriparatida não se mostrou custo-efetiva em nenhuma situação. A única alternativa em que ela mostrou possibilidades de ser custo efetiva foi em pacientes utilizando glicocorticóides. O impacto orçamentário de acordo com o market share variou de 9 milhões com AVC e 117 milhões para homens com ostorporose e falha terapêutica. RECOMENDAÇÃO PRELIMINAR DA CONITEC: Embora a teriparatida só se mostre custo-efetiva para pacientes usando glicocorticóides e não haja economia de recursos, os membros do Comitê de Medicamentos, na 129ª reunião ordinária da Conitec, realizada no dia 8 de maio de 2024, deliberaram, por unanimidade, que a matéria fosse disponibilizada em consulta pública com recomendação preliminar favorável à restrição do uso da teriparatida para o tratamento no SUS da osteoporose em falha terapêutica para: (a) homens; (b) pacientes com osteoporose severa por uso de glicocorticoides (GC); (c) pacientes com acidente vascular cerebral (AVC) no ano anterior; e d) pacientes com infarto agudo do miocárdio (IAM) no ano anterior, haja vista que esses pacientes não são atendidos com as opções terapêuticas disponíveis no SUS. CONSULTA PÚBLICA: A Consulta Pública nº 040 foi realizada entre os dias 26/06/2024 e 15/07/2024. Foram recebidas 6 contribuições, todas de cunho técnico-científico. No total, 1 não concordou e não discordou da recomendação inicial da Conitec, 1 concordou e 4 discordaram. Embora as evidências clínicas não fossem objeto da análise do relatório da consulta pública, todos os participantes que discordaram da restrição do uso da teriparatida relataram a necessidade do uso do medicamento em pacientes com osteoporose grave. Nenhuma das contribuições sobre avaliação econômica apresentou argumentos, indicando apenas uma bibliografia genérica sobre a eficácia do teriparatida. A empresa argumentou que existe evidências da segurança, eficácia e efetividade nos ensaios clínicos e que houve uma autorização de aumento de 4,5% pela CMED que não foi repassado aos preços. Confirmou o preço da última proposta de R$ 12.282,06 para o fornecimento da teriparatida se as restrições fossem aprovadas As das contribuições recebidas na Consulta Pública não trouxeram novos fundamentos na parte econômica que justificassem a alteração da decisão preliminar. As evidências clínicas não estavam em avaliação e não foram objeto de análise. RECOMENDAÇÃO FINAL DA CONITEC: Através do registro de deliberação nº 918/2024, os membros do Comitê de Medicamentos, presentes na 132ª Reunião ordinária da Conitec, realizada no dia 07 de agosto de 2024, deliberaram por maioria pela recomendação FAVORÁVEL pela exclusão da teriparatida para o tratamento de osteoporose grave. O Comitê considerou que a terapia não era custo-efetiva nos cenários apresentados e uma alternativa mais econômica e conveniente estaria disponível em um horizonte tecnológico curto. DECISÃO: excluir, no âmbito do Sistema Único de Saúde - SUS, a teriparatida para o tratamento da osteoporose grave e falha terapêutica aos medicamentos disponíveis no SUS, publicada no Diário Oficial da União, número 183, Seção 1, página 147, em 20 de setembro de 2024.
Assuntos
Humanos , Osteoporose/etiologia , Teriparatida/uso terapêutico , Acidente Vascular Cerebral/fisiopatologia , Glucocorticoides/efeitos adversos , Infarto do Miocárdio/fisiopatologia , Sistema Único de Saúde , Brasil , Eficácia , Análise Custo-Benefício/economiaRESUMO
PURPOSE: Physical inactivity is considered an important risk factor for osteoporosis, however, some athletes performing extremely high training volumes can also develop bone mass loss. Moreover, the effect of total body mass or body surface area on bone mineral density remains controversial. Therefore, the aim of this study was to compare the absolute bone mineral density and bone mineral density adjusted to body surface area between amateur triathletes and nonactive women. METHODS: Forty-two healthy women (23 amateur triathletes and 19 nonactive individuals) were evaluated for body composition using a dual-energy X-ray absorptiometry system. RESULTS: Compared to nonactive women, amateur triathletes exhibited lower body mass index (p < 0.001), lower bone mineral density (p < 0.001), and body surface area (p < 0.001). However, bone mineral density adjusted by body surface area in the triathletes was higher than in the nonactive women (p = 0.03). CONCLUSION: These findings showed that amateur triathles presented lower absolute bone mineral density, but higher bone mineral density adjusted to body surface area. Future studies are recommended to identify if the higher bone mineral density adjusted to body surface area are associated with a lower bone fragility.
Assuntos
Absorciometria de Fóton , Atletas , Densidade Óssea , Humanos , Densidade Óssea/fisiologia , Feminino , Estudos Transversais , Adulto , Pessoa de Meia-Idade , Composição Corporal/fisiologia , Índice de Massa Corporal , Natação/fisiologia , Osteoporose/fisiopatologia , Osteoporose/diagnóstico por imagemRESUMO
Alzheimer's disease (AD) and osteoporosis are two diseases that mainly affect elderly people, with increases in the occurrence of cases due to a longer life expectancy. Several epidemiological studies have shown a reciprocal association between both diseases, finding an increase in incidence of osteoporosis in patients with AD, and a higher burden of AD in osteoporotic patients. This epidemiological relationship has motivated the search for molecules, genes, signaling pathways and mechanisms that are related to both pathologies. The mechanisms found in these studies can serve to improve treatments and establish better patient care protocols.
Assuntos
Doença de Alzheimer , Osteoporose , Humanos , Doença de Alzheimer/epidemiologia , Osteoporose/epidemiologia , IncidênciaRESUMO
Osteoporosis is a globally relevant public health issue. Our study aimed to summarize the knowledge on the proteomic biomarkers for low bone mineral density over the last years. We conducted a systematic review following the PRISMA guidelines; the scoured databases were PubMed, Web of Sciences, Scopus, and EBSCO, from inception to 2 June 2023. A total of 610 relevant studies were identified and 33 were assessed for eligibility. Finally, 29 studies met the criteria for this systematic review. The risk of bias was evaluated using the Joanna Briggs Institute Critical Appraisal Checklist tool. From the studies selected, 154 proteins were associated with changes of bone mineral density, from which only 10 were reported in at least two articles. The protein-protein network analysis indicated potential biomarkers involved in the skeletal system, immune system process, regulation of protein metabolic process, regulation of signaling, transport, cellular component assembly, cell differentiation, hemostasis, and extracellular matrix organization. Mass spectrometry-based proteomic profiling has allowed the discovery of new biomarkers with diagnostic potential. However, it is necessary to compare and validate the potential biomarkers in different populations to determine their association with bone metabolism and evaluate their translation to the clinical management of osteoporosis.